Sugi Predict

Sugi Predict / Targets / ATRIP

ATRIP

ATR-interacting protein (ATM and Rad3-related · Q8WXE1 · ATRIP on Sugi Atlas →

18,199 patent compounds predicted against ATRIP, 9,783 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2077611 SCHEMBL2077611 0.56 18/20
SCHEMBL2080180 SCHEMBL2080180 0.56 18/20
SCHEMBL2369755 SCHEMBL2369755 0.47 16/20
SCHEMBL2369762 SCHEMBL2369762 0.47 16/20
SCHEMBL2079418 SCHEMBL2079418 0.58 15/20
SCHEMBL2078868 SCHEMBL2078868 0.56 15/20
SCHEMBL796862 SCHEMBL796862 0.55 15/20
SCHEMBL796636 SCHEMBL796636 0.50 15/20
SCHEMBL2369782 SCHEMBL2369782 0.47 13/20
SCHEMBL2369785 SCHEMBL2369785 0.47 13/20
SCHEMBL2369424 SCHEMBL2369424 0.52 12/20
SCHEMBL2369429 SCHEMBL2369429 0.52 12/20
SCHEMBL3091820 SCHEMBL3091820 0.53 11/20
SCHEMBL3080008 SCHEMBL3080008 0.51 11/20
SCHEMBL738140 SCHEMBL738140 0.49 11/20
SCHEMBL2487507 SCHEMBL2487507 0.49 11/20
SCHEMBL2487510 SCHEMBL2487510 0.49 11/20
SCHEMBL3077782 SCHEMBL3077782 0.47 11/20
SCHEMBL3588712 SCHEMBL3588712 0.46 11/20
SCHEMBL2493212 SCHEMBL2493212 0.45 11/20

Clinical trials — most relevant to ATRIP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations PHASE2COMPLETED
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors PHASE2COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
AZD6738 for Patients With Progressive MDS or CMML PHASE1ACTIVE_NOT_RECRUITING
M6620 Plus Standard Treatment in Oesophageal and Other Cancer PHASE1COMPLETED
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetics of Prostate Cancer in Young Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ATRIP binder may also engage these)

ProteinNameSimilarity
Q9N077 — 1.000 Q9N077 →
Q3U1D0 — 0.997 Q3U1D0 →
Q8BMG1 — 0.995 Q8BMG1 →
Q3UJB9 — 0.994 Q3UJB9 →
Q7Z2Z1 — 0.993 Q7Z2Z1 →
Q9Y6A5 — 0.992 Q9Y6A5 →
O88480 — 0.992 O88480 →
Q6P2H3 — 0.992 Q6P2H3 →
Q8TF30 — 0.992 Q8TF30 →
Q3SYW0 — 0.991 Q3SYW0 →
Q80TQ5 — 0.991 Q80TQ5 →
Q8IWE5 — 0.991 Q8IWE5 →
O75800 — 0.990 O75800 →
Q15345 — 0.990 Q15345 →
E1U8D0 — 0.990 E1U8D0 →
Q6ZS81 — 0.990 Q6ZS81 →
Q9EQR6 — 0.990 Q9EQR6 →
Q8VC34 — 0.989 Q8VC34 →
Q0KK56 — 0.989 Q0KK56 →
Q3U6Q4 — 0.989 Q3U6Q4 →
Q5RAJ5 — 0.989 Q5RAJ5 →
Q92543 — 0.989 Q92543 →
Q3UHQ6 — 0.989 Q3UHQ6 →
Q96C34 — 0.989 Q96C34 →
Q58CQ0 — 0.989 Q58CQ0 →
Q569K6 — 0.989 Q569K6 →
Q5SZL2 — 0.989 Q5SZL2 →
B1A193 — 0.988 B1A193 →
Q8BQ33 — 0.988 Q8BQ33 →
Q6P1H6 — 0.988 Q6P1H6 →